Study
Clinical intervention studies with resveratrol: a review
A phase II trial in Alzheimer's, a PREDIMED substudy, and a small obesity trial together illustrate why resveratrol results depend on dose and population.
Summary Does resveratrol improve health in different groups of people? Show / hide ↓
This review summarized three human studies involving 1,164 people. In a 52-week Alzheimer’s study, 119 people took increasing doses, up to 1,000 milligrams twice daily; the treatment was generally safe and changed some brain-fluid markers linked with inflammation. A separate study of 1,000 people found that those with more resveratrol breakdown products in their urine also tended to have lower blood sugar and triglycerides, a type of blood fat, but this did not prove resveratrol caused the change. In a four-week crossover trial, 45 overweight adults took 150 milligrams daily and then a comparison treatment, with neither affecting heart-risk measures, blood-vessel function, or inflammation. The results therefore differed by dose, health group, and outcome measured.
What this means for you: This review does not show that most people should buy or take resveratrol. The Alzheimer’s findings are promising but involve biological markers rather than clear proof of better memory or longer life, while the small obesity study found no benefit.
conflicting evidenceThis review walks through the three clinical arcs that shaped how resveratrol is now used in research. First, a 52-week phase II trial in mild-to-moderate Alzheimer's (n=119) escalating from 500 mg per day to 1,000 mg twice per day found the molecule was safe and well tolerated, reduced Aβ40 and MMP9 in cerebrospinal fluid, and modulated neuroinflammation. Second, a substudy of PREDIMED (n=1,000, type-2 diabetics or high-cardiovascular-risk adults) showed higher urinary resveratrol metabolites correlated with lower fasting glucose and triglycerides. Third, a crossover RCT of 45 overweight adults on 150 mg per day for four weeks found no effect on cardiovascular risk markers, endothelial function, or inflammation. Same molecule, three different populations and dose ranges, three different signals. The pattern favors metabolic and neurological subgroups over healthy adults.
Effects of resveratrol in human trials are heterogeneous and appear to depend strongly on dose and baseline population.
PREDIMED was observational not interventional for resveratrol specifically. The Alzheimer's phase II did not show clinical improvement, only biomarker shifts.
Cited by
1 encyclopedia entries reference this study.